Effect of elexacaftor/tezacaftor/ivacaftor on the use of routine therapies in Danish people with cystic fibrosis
Two-year follow-up results from an ongoing study on the safety and effectiveness of elexacaftor/tezacaftor/ivacaftor when used in real-world settings by people with cystic fibrosis
More favorable growth profiles in early childhood are associated with higher lung function at age six
How changes in health insurance coverage for young children with CF can impact important health outcomes, such as lung function at 6 years of age
How does infection with Pseudomonas and Aspergillus affect people with cystic fibrosis? A study using UK registry data.
Changing epidemiology of the respiratory bacteriology of patients with cystic fibrosis-data from the European cystic fibrosis society patient registry.
